Page 39 - Johnson Amp News Today

The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.

A bankruptcy court’s ruling was the second time the company was rebuffed in its attempt to settle thousands of lawsuits that claim its products caused cancer.

Johnson & Johnsons proposed $8.9bn settlement to resolve tens of thousands of lawsuits over its talc products has been imperilled. US Bankruptcy Judge Michael Kaplan rejected the healthcare companys second attempt to resolve the cases in bankruptcy, stating that financial distress had not forced the company to act. Plaintiffs have lodged mass lawsuits alleging that Johnson & Johnsons baby powder and other talc products caused mesothelioma, ovarian cancer and other cancers.

The industry has launched a legal war against a new law that would let Medicare negotiate prices for some medicines. The odds are in Big Pharma's favor.

The decision jeopardizes J&J's proposed $8.9 billion settlement that would stop new lawsuits over its talc baby powder and other products from being filed.

A New Jersey bankruptcy judge threw out the second chapter 11 case that Johnson & Johnson filed to resolve its mass talc liabilities, again shutting down the healthcare-product company’s plan to achieve an $8.9 billion settlement.

U.S. Bankruptcy Judge Michael Kaplan ruled that J&J company’s second bankruptcy must, like its first, be dismissed as the company was not in ‘financial distress’

Johnson & Johnson (NYSE:JNJ – Free Report) had its price objective increased by Raymond James from $181.00 to $184.00 in a research note issued to investors on Monday, Benzinga reports. The brokerage currently has an outperform rating on the stock. Other analysts have also recently issued research reports about the stock. TheStreet cut shares of […]

Johnson & Johnson (NYSE:JNJ – Free Report) had its target price upped by Raymond James from $181.00 to $184.00 in a report issued on Monday morning, Benzinga reports. They currently have an outperform rating on the stock. Several other brokerages have also issued reports on JNJ. Stifel Nicolaus raised their target price on shares of […]

Johnson & Johnson (JNJ) has been the best-performing Club stock in the Dow Jones Industrial Average during its 13-session winning streak.